[
  {
    "ts": null,
    "headline": "Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?",
    "summary": "The highest-yielding stocks in the Dow are Verizon, Chevron, and Merck, but should you buy any of them?",
    "url": "https://finnhub.io/api/news?id=d41839b81804fadf55f7f74b8ce434f5c826793e823acf4fdb472386360955df",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767647100,
      "headline": "Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?",
      "id": 137997800,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The highest-yielding stocks in the Dow are Verizon, Chevron, and Merck, but should you buy any of them?",
      "url": "https://finnhub.io/api/news?id=d41839b81804fadf55f7f74b8ce434f5c826793e823acf4fdb472386360955df"
    }
  },
  {
    "ts": null,
    "headline": "Merck to Participate in the 44th Annual J.P. Morgan Healthcare Conference",
    "summary": "RAHWAY, N.J., January 05, 2026--Merck to Participate in the 44th Annual J.P. Morgan Healthcare Conference",
    "url": "https://finnhub.io/api/news?id=954e4cc04a6ba9665af62ff0a671e88e22ac963f57ccd4dc210b9d5837063443",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767613500,
      "headline": "Merck to Participate in the 44th Annual J.P. Morgan Healthcare Conference",
      "id": 137991176,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., January 05, 2026--Merck to Participate in the 44th Annual J.P. Morgan Healthcare Conference",
      "url": "https://finnhub.io/api/news?id=954e4cc04a6ba9665af62ff0a671e88e22ac963f57ccd4dc210b9d5837063443"
    }
  },
  {
    "ts": null,
    "headline": "Sterility Testing Market to Reach US$ 3,913.35 Million by 2035 Amid Rising Global Clinical Trial Activity Says Astute Analytica",
    "summary": "Robust expansion currently defines the landscape as major players like Eli Lilly and Merck aggressively fund new manufacturing facilities. Concurrently, the industry embraces rapid technological advancements in automated membrane filtration to streamline critical quality assurance processes.Chicago, Jan. 05, 2026 (GLOBE NEWSWIRE) -- The global sterility testing market was valued at US$ 1,344.31 million in 2025 and is expected to reach US$ 3,913.35 million by 2035, growing at a CAGR of 11.36% dur",
    "url": "https://finnhub.io/api/news?id=3ebf6c2c964e3b56c2ee198293a841431e74119e2bd0324ce94bd5751fa1948d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767601800,
      "headline": "Sterility Testing Market to Reach US$ 3,913.35 Million by 2035 Amid Rising Global Clinical Trial Activity Says Astute Analytica",
      "id": 137991014,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Robust expansion currently defines the landscape as major players like Eli Lilly and Merck aggressively fund new manufacturing facilities. Concurrently, the industry embraces rapid technological advancements in automated membrane filtration to streamline critical quality assurance processes.Chicago, Jan. 05, 2026 (GLOBE NEWSWIRE) -- The global sterility testing market was valued at US$ 1,344.31 million in 2025 and is expected to reach US$ 3,913.35 million by 2035, growing at a CAGR of 11.36% dur",
      "url": "https://finnhub.io/api/news?id=3ebf6c2c964e3b56c2ee198293a841431e74119e2bd0324ce94bd5751fa1948d"
    }
  },
  {
    "ts": null,
    "headline": "BioInvent Reports Promising Data from Ongoing Phase 2a study for BI-1808 with KEYTRUDA(R) (pembrolizumab) in Recurrent Ovarian Cancer",
    "summary": "24% ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ovarian cancer (8% ORR in KEYNOTE-100) The combination demonstrated a favorable safety and tolerability profile Results ...",
    "url": "https://finnhub.io/api/news?id=42e61129d5567feeb60f44c1c675967ce5cf20b0ca0c8d31b72dad768a90f62b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767595500,
      "headline": "BioInvent Reports Promising Data from Ongoing Phase 2a study for BI-1808 with KEYTRUDA(R) (pembrolizumab) in Recurrent Ovarian Cancer",
      "id": 137991178,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "24% ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ovarian cancer (8% ORR in KEYNOTE-100) The combination demonstrated a favorable safety and tolerability profile Results ...",
      "url": "https://finnhub.io/api/news?id=42e61129d5567feeb60f44c1c675967ce5cf20b0ca0c8d31b72dad768a90f62b"
    }
  },
  {
    "ts": null,
    "headline": "Is Merck Still Attractive at $106 After Recent Gains and Pipeline Progress?",
    "summary": "Wondering if Merck at around $106 is still a smart buy or if most of the upside is already priced in? This breakdown will help you decide whether the market is being too cautious or not cautious enough. Despite a flat return year to date and a modest 1.6% gain over three years, the stock has climbed 6.7% in the last month and 11.4% over the past year, hinting that sentiment around Merck's long term prospects is quietly improving. Recently, attention has centered on Merck's late stage...",
    "url": "https://finnhub.io/api/news?id=7c489b5a28506e909e3b00779e34680e3edf46f487f1ba76146125b557b0afca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767582602,
      "headline": "Is Merck Still Attractive at $106 After Recent Gains and Pipeline Progress?",
      "id": 137986046,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Wondering if Merck at around $106 is still a smart buy or if most of the upside is already priced in? This breakdown will help you decide whether the market is being too cautious or not cautious enough. Despite a flat return year to date and a modest 1.6% gain over three years, the stock has climbed 6.7% in the last month and 11.4% over the past year, hinting that sentiment around Merck's long term prospects is quietly improving. Recently, attention has centered on Merck's late stage...",
      "url": "https://finnhub.io/api/news?id=7c489b5a28506e909e3b00779e34680e3edf46f487f1ba76146125b557b0afca"
    }
  }
]